AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23283585
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 0.5 Gy
Trial: 23283585
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 1.0 Gy
Trial: 10866886
Drug: 0.07 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.07 mg/kg morphine (M1)
Trial: 10866886
Drug: 0.14 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.14 mg/kg morphine (M2)
Trial: 10866886
Drug: 0.14 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.14 mg/kg oxycodone (O)
Trial: 9083824
Drug: Intensive outpatient
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive outpatient treatment (INT)
Trial: 16231341
Drug: Individual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual therapy (IND)
Trial: 9083824
Drug: Individual plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual plus group therapy (IND-GRP)
Trial: 8212201
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (no prophylactic ALG)
Trial: 8212201
Drug: Immediate CsA
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate CsA group (triple therapy)
Trial: 3544690
Drug: Bendroflumethiazide 2.5‐5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendroflumethiazide 2.5‐5 mg/day
Trial: 3544690
Drug: Propranolol 160‐320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 160‐320 mg daily
Trial: 29398422
Drug: Current users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current users of hormone replacement therapy
Trial: 29398422
Drug: Never-users of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Never-users of hormone replacement therapy
Trial: 9565436
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin A supplements
Trial: 23633748
Drug: Baseline (drug-free)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline (drug-free) nights
Trial: 17100860
Drug: Interactive educational
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive educational programme for peer review groups focusing on treatment of chronic heart failure (CHF)
Trial: 17100860
Drug: Interactive educational
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive educational programme for peer review groups focusing on hypertension treatment in diabetes mellitus type 2 (T2DM)
Trial: 14675803
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (24 IU) with social support from a best friend
Trial: 14675803
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (24 IU) without social support
Trial: 3839424
Drug: Sequential non-cross
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential non-cross resistant combinations (CMFP-AV) at full dose
Trial: 18072822
Drug: HEP-40 2,400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEP-40 2,400 mg once daily
Trial: 18072822
Drug: HEP-40 400
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEP-40 400 mg three times daily
Trial: 15613421
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone (Intrinsa, 150 mug)
Trial: 15613421
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone (Intrinsa, 300 mug)
Trial: 30726946
Drug: High dietary
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dietary insulin load in patients with obesity
Trial: 28320345
Drug: Telephone follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone follow-up at 8, 30, and 60 days after treatment for attempted suicide
Trial: 19300199
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (continued steroids)
Trial: 15156427
Drug: Directly Administered
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directly Administered Antiretroviral Therapy (DAART) program, 1 of 2 daily HAART doses, 5 days per week for 6 months
Trial: 8001212
Drug: Omeprazole (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (two doses)
Trial: 2123152
Drug: rt-PA (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rt-PA (0.6 mg/kg, 2-minute infusion)
Trial: 363702
Drug: Fixed standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed standard dosage (20 mg/day)
Trial: 31447409
Drug: 40 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 μg teriparatide + denosumab 60 mg every 6 months
Trial: 31447409
Drug: 20 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg teriparatide + denosumab 60 mg every 6 months
Trial: 21325465
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg phytoestrogens
Trial: 21325465
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg phytoestrogens
Trial: 19264792
Drug: CoPAT (Outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoPAT (Outpatient parenteral antimicrobial therapy)
Trial: 19264792
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (semi‐synthetic penicillin or vancomycin with initial low‐dose gentamicin)
Trial: 1968319
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg dipotassium chlorazepate (DC)
Trial: 6992913
Drug: Plain catgut
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain catgut subcutaneous fat stitch
Trial: 29908043
Drug: PF-06741086 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06741086 (30 mg subcutaneously to 440 mg intravenously)
Trial: 8726950
Drug: Inhaled glucocorticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled glucocorticosteroids
Trial: 1283117
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day finasteride
Trial: 2157231
Drug: Gepirone 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepirone 10 mg
Trial: 2157231
Drug: Gepirone 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepirone 20 mg
Trial: 30913943
Drug: TENS combined
RxNorm normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TENS combined with traditional physical therapy
Trial: 30913943
Drug: Traditional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional physical therapy (Control)
Trial: 28321022
Drug: Ticagrelor (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (90 mg twice-daily)
Trial: 28321022
Drug: Clopidogrel (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (150 mg once-daily)
Trial: 11038410
Drug: 5.5% CHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.5% CHO solution (8 ml (kg body mass (BM))‐1)
Trial: 11038410
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution (CON trial)
Trial: 22081005
Drug: Amlodipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (10 mg/day)
Trial: 8860111
Drug: Ibuprofen (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (400 mg, three times a day for 3 days)
Trial: 31445316
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (olive oil capsules)
Trial: 24939630
Drug: Trans-cervical double
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trans-cervical double balloon catheter with extra-amniotic saline infusion (EASI)
Trial: 24939630
Drug: Trans-cervical double
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trans-cervical double balloon catheter without extra-amniotic saline infusion (Control)
Trial: 15305887
Drug: glimepiride 1-6
RxNorm normalized name: glimepiride 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glimepiride 1-6 mg daily
Trial: 31322915
Drug: Pelvic side
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic side wall boost (dose not specified)
Trial: 29231608
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia combined with EA pretreatment at Zusanli (ST 36), Shangjuxu (ST 37), Xiajuxu (ST 39), Tianshu (ST 25) and Zhongwan (CV 12)
Trial: 29231608
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia combined with EA pretreatment at Zusanli (ST 36), Shangjuxu (ST 37), Xiajuxu (ST 39)
Trial: 18279411
Drug: Continuous physiotherapy
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous physiotherapy (once or twice a week for a total of 30 weeks)
Trial: 16413647
Drug: New treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New treatments for OCD
Trial: 10591286
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ecopipam
Trial: 10591286
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg ecopipam
Trial: 10591286
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg ecopipam
Trial: 6462734
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose nitrofurantoin
Trial: 22691567
Drug: Citicoline (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline (1000 mg every 12 h intravenously during the first 3 days and orally thereafter for a total of 6 weeks [2×500 mg oral tablets given every 12 h])
Trial: 2254558
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose amiodarone, 200 mg/day (Group 2, n = 98)
Trial: 2254558
Drug: Individually treated
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually treated antiarrhythmic therapy (Group 1, n = 100)
Trial: 2254558
Drug: No antiarrhythmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiarrhythmic therapy (Group 3 [control group], n = 114)
Trial: 6994772
Drug: guanfacine 2
RxNorm normalized name: guanfacine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guanfacine 2 mg daily
Trial: 1817051
Drug: placebo preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo preparation
Trial: 31610073
Drug: Telehealth treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telehealth treatment (after all parents received it)
Trial: 31610073
Drug: Telehealth treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telehealth treatment (for children who entered treatment above target)
Trial: 1693055
Drug: 1-hour infusion
RxNorm normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-hour infusion of vancomycin (1.0 g)
Trial: 1693055
Drug: 2-hour infusion
RxNorm normalized name: Interleukin-2/diptheria toxin fusion protein
DrugBank: Denileukin diftitox (DB00004)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-hour infusion of vancomycin (1.0 g)
Trial: 6112564
Drug: Heparin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin and Atenolol combined
Trial: 24556154
Drug: Alcohol administration
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol administration after overnight smoking deprivation
Trial: 23158941
Drug: Qigong intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Qigong intervention (specific exercises developed by the Heidelberg School of Chinese Medicine)
Trial: 19825948
Drug: Lapatinib 175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 175 to 1,800 mg once daily
Trial: 19825948
Drug: Lapatinib 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 500 to 900 mg twice daily
Trial: 9454525
Drug: Troglitazone 400
RxNorm normalized name: troglitazone 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone 400 mg/d
Trial: 15617954
Drug: Troglitazone 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone 600 mg/d
Trial: 11782871
Drug: Troglitazone (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (both doses)
Trial: 2648911
Drug: 4 months
RxNorm normalized name: leuprolide 30 mg/4 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 months of daily chemotherapy with streptomycin, isoniazid, rifampin, and pyrazinamide
Trial: 2648911
Drug: 4 months
RxNorm normalized name: leuprolide 30 mg/4 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 months of chemotherapy (3 times a week)
Trial: 2648911
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months of daily chemotherapy with streptomycin, isoniazid, rifampin, and pyrazinamide
Trial: 24279284
Drug: Structured diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured diabetes education plus insulin therapy
Trial: 24279284
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus insulin therapy
Trial: 22577038
Drug: Pregabalin 75
RxNorm normalized name: pregabalin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 75 mg, administered 3 times daily for 3 days
Trial: 22577038
Drug: Gabapentin 300
RxNorm normalized name: gabapentin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 300 mg, administered 3 times daily for 3 days
Trial: 22577038
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered 3 times daily for 3 days
Trial: 12601115
Drug: Phenylalanine loading
RxNorm normalized name: Phenylalanine
DrugBank: Phenylalanine (DB00120)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylalanine loading test (Phe-L)
Trial: 8872499
Drug: IVIG 200
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG 200 mg/kg
Trial: 8872499
Drug: IVIG 400
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG 400 mg/kg
Trial: 8872499
Drug: IVIG 600
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG 600 mg/kg
Trial: 28705172
Drug: Rimonabant (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimonabant (20 mg od)
Trial: 28705172
Drug: Orlistat (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (120 mg tds)
Trial: 28705172
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg tds)
Trial: 28705172
Drug: Pioglitazone (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (45 mg od)
Trial: 16495704
Drug: BALI model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BALI model (4-variable prognostic model including BUN >or=25 mg/dL, Age >or=65 years, LDH >or=300 IU/L, IL‐6 >or=300 pg/mL)
Trial: 15297138
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose conformal radiotherapy (CFRT) at 74 Gy
Trial: 6409208
Drug: Thiazides (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazides (long-term treatment)
Trial: 6409208
Drug: Amiloride (substitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride (substitution for thiazides in long-term treatment)
Trial: 28679772
Drug: Detection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of ≥1 CTC/7.5 mL before NT
Trial: 28679772
Drug: Detection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of ≥2 CTCs/7.5 mL before NT
Trial: 28679772
Drug: Detection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of ≥2 CTCs/7.5 mL before NT in HER2-positive and triple-negative patients
Trial: 19675499
Drug: Control (CON)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (CON) (no treatment)
Trial: 31305347
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without any treatment
Trial: 17368254
Drug: Oxytocin infusion
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin infusion (2 ampules of oxytocin at 10 u/mL/amp added to 1000 mL saline at 40 mU/min)
Trial: 15559351
Drug: No oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No oxytocin infusion (control group)
Trial: 11698316
Drug: Local administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local administration of meloxicam 7.5 mg
Trial: 11698316
Drug: i.v. administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. administration of meloxicam 7.5 mg
Trial: 9383806
Drug: GM-CSF (Leucomax,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF (Leucomax, 5 micrograms/kg) administered subcutaneously for 10 days after chemotherapy
Trial: 8031548
Drug: Hydrochlorothiazide (added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (added if monotherapy was inadequate)
Trial: 26289810
Drug: High-intensity intermittent
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity intermittent activities coupled with aerobic training (3 sessions of 60 minutes weekly for 8 weeks)
Trial: 18165593
Drug: Nimesulide 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide 90 mg orally twice daily
Trial: 8472517
Drug: ST-679 at
RxNorm normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ST-679 at 600 mg/die
Trial: 8472517
Drug: ST-679 at
RxNorm normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ST-679 at 1200 mg/die
Trial: 8472517
Drug: ST-679 at
RxNorm normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ST-679 at 1800 mg/die
Trial: 8472517
Drug: Placebo (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (600 mg/die)
Trial: 18799426
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of naltrexone
Trial: 27401364
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg EPA+DHA daily for 52 weeks
Trial: 27401364
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg EPA+DHA daily for 52 weeks
Trial: 20608252
Drug: Drugs approved
RxNorm normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drugs approved based on surrogate endpoint trials
Trial: 2185673
Drug: Sublingual captopril
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual captopril 12.5 mg
Trial: 2185673
Drug: Sublingual captopril
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual captopril 25 mg
Trial: 2185673
Drug: Sublingual captopril
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual captopril (both doses)
Trial: 23387416
Drug: IMAAC (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMAAC (600 mg)
Trial: 23387416
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate (600 mg)
Trial: 11793035
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (oral tacrolimus 0.2 mg/kg daily + oral prednisone + oral azathioprine)
Trial: 9551778
Drug: placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets and placebo patch
Trial: 7998359
Drug: Padma-28 (340
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Padma-28 (340 mg dried herbal mixture, 2 tablets twice daily for four months)
Trial: 3176957
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion epidural analgesia (EDA) with bupivacaine throughout delivery (group B)